STEREOTAXIS INC

NYSE: STXS (Stereotaxis, Inc.)

Last update: 07 Jan, 12:16AM

2.64

0.27 (11.39%)

Previous Close 2.37
Open 2.53
Volume 923,842
Avg. Volume (3M) 338,855
Market Cap 223,685,904
Price / Sales 7.66
Price / Book 17.94
52 Weeks Range
1.66 (-37%) — 3.29 (24%)
Earnings Date 3 Mar 2025 - 7 Mar 2025
Profit Margin -85.79%
Operating Margin (TTM) -69.00%
Diluted EPS (TTM) -0.270
Quarterly Revenue Growth (YOY) 17.90%
Total Debt/Equity (MRQ) 37.82%
Current Ratio (MRQ) 1.39
Operating Cash Flow (TTM) -8.84 M
Levered Free Cash Flow (TTM) -2.16 M
Return on Assets (TTM) -29.35%
Return on Equity (TTM) -106.46%

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Bullish Mixed
Medical Instruments & Supplies (Global) Mixed Mixed
Stock Stereotaxis, Inc. - -

AIStockmoo Score

-0.2
Analyst Consensus 2.0
Insider Activity 1.5
Price Volatility -4.5
Technical Moving Averages 1.5
Technical Oscillators -1.5
Average -0.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
STXS 224 M - - 17.94
INFU 143 M - 671.00 3.05
MLSS 69 M - - 12.73
RVP 23 M - - 0.270
ALC 44 B 0.30% 42.50 2.32
RMD 34 B 0.87% 30.77 6.70

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

Sector Healthcare
Industry Medical Instruments & Supplies
% Held by Insiders 15.64%
% Held by Institutions 48.55%

Ownership

Name Date Shares Held
Lagoda Investment Management, L.P. 30 Sep 2024 3,830,435
Arbiter Partners Capital Management Llc 30 Sep 2024 2,791,068
Archon Capital Management Llc 30 Sep 2024 1,283,897
Alphacentric Advisors Llc 30 Sep 2024 600,000
Legato Capital Management Llc 30 Sep 2024 472,150

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BENFER DAVID 2.29 - 56,497 129,378
CURET MYRIAM 2.29 - 56,497 129,378
FISCHEL NATHAN 2.29 - 56,497 129,378
LEVIN ROSS B 2.29 - 56,497 129,378
MENAWAT ARUN SWARUP 2.29 - 56,497 129,378
SHAMIR NACHUM 2.29 - 45,608 104,442
Aggregate Net Quantity 328,093
Aggregate Net Value ($) 751,333
Aggregate Avg. Buy ($) 2.29
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
BENFER DAVID Director 02 Jan 2025 Acquired (+) 56,497 2.29 129,378
CURET MYRIAM Director 02 Jan 2025 Acquired (+) 56,497 2.29 129,378
SHAMIR NACHUM Director 02 Jan 2025 Acquired (+) 45,608 2.29 104,442
LEVIN ROSS B Director 02 Jan 2025 Acquired (+) 56,497 2.29 129,378
FISCHEL NATHAN Director 02 Jan 2025 Acquired (+) 56,497 2.29 129,378
MENAWAT ARUN SWARUP Director 02 Jan 2025 Acquired (+) 56,497 2.29 129,378

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria